MARKET

ALLR

ALLR

Allarity
NASDAQ
0.3150
+0.0060
+1.94%
Opening 14:56 03/27 EDT
OPEN
0.3100
PREV CLOSE
0.3090
HIGH
0.3298
LOW
0.3020
VOLUME
76.96K
TURNOVER
0
52 WEEK HIGH
154.40
52 WEEK LOW
0.3000
MARKET CAP
1.95M
P/E (TTM)
-0.0307
1D
5D
1M
3M
1Y
5Y
Allarity Therapeutics Granted Extension for Nasdaq Compliance
TipRanks · 1d ago
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Stoke Therapeutics stock is rocketing more than 81% alongside positive Phase 1/2a studies data. The biggest pre-market stock movers on Tuesday are pharmaceutical updates, earnings reports, collaboration agreements and more. Tidal Trust II YieldMax MRNA Option Income Strategy ETF (MRNY) stock is plummeting 60% this morning.
Investorplace · 1d ago
Weekly Report: what happened at ALLR last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at ALLR last week (0311-0315)?
Weekly Report · 03/18 10:26
Weekly Report: what happened at ALLR last week (0304-0308)?
Weekly Report · 03/11 10:24
Allarity Therapeutics: Q4 Earnings Insights
Allarity Therapeutics missed estimated earnings by -36.0%. The company reported its Q4 earnings of $-0.34. Last quarter the company beat on EPS by $5.93. The company is expected to report its earnings on March 8, 2024.
Benzinga · 03/08 14:15
Allarity: Other definitive proxy statementsOpen document
Press release · 03/08 14:06
Allarity Therapeutics Issues Regulation FD Disclosure Notice
Allarity Therapeutics, Inc. (ALLR) recently made financial disclosures. The company remains noncommittal on the significance of the information. Allarity is a biopharmaceutical company that is developing a drug to treat cancer. The announcement is linked to a Current Report on Form 8-K.
TipRanks · 03/08 13:52
More
About ALLR
Allarity Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is focused on development of stenoparib, a poly-ADP-ribose polymerase/Tankyrase inhibitor for advanced ovarian cancer patients, using its DRP companion diagnostic for patient selection in the ongoing phase 2 clinical trial, NCT03878849. It has in-licensed the intellectual property rights to develop, use and market stenoparib. Its DRP companion diagnostic platform is a predictive biomarker technology that employs complex systems biology and bio-analytics with a clinical relevance filter to bridge the gap between in vitro cancer cell responsiveness to a given therapeutic candidate and in vivo likelihood of actual patient benefit from that therapeutic candidate. Its DRP companion diagnostic platform provides a gene expression signature, which reveals whether a specific tumor in a specific patient is likely to respond to one of its therapeutic candidates.

Webull offers Allarity Therapeutics Inc stock information, including NASDAQ: ALLR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALLR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALLR stock methods without spending real money on the virtual paper trading platform.